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Introduction
JanusMatrix is a new immunoinformatics tool that was developed 
to compare T cell epitope conservation between protein sequences 
from bacterial and viral organisms that make up the human gut 
microbiome (HM), autologous proteins from the human genome 
(HG), and human viral and bacterial pathogens (HP). We have 
used JanusMatrix to initiate the exploration of the relationships 
between conservation with self (and non-self), T cell phenotype 
(regulatory or effector), and immunodominance. For example, 
we postulated that regulatory T cells (Treg) might bear T cell 
receptors (TCRs) that are more likely to bind to T cell epitopes 
that are cross-conserved (at the TCR face) in many human (self) 
proteins, while, by comparison true effector T cells (Teff) might 
bear TCRs that recognize TCR-facing residues that are less cross-
conserved with human genome proteins. We reasoned that such 
advances in the field of T cell immunology have contributed to the understanding that cross-reactivity is an intrinsic 
characteristic of the T cell receptor (TcR), and that each TcR can potentially interact with many different T cell epitopes. 
To better define the potential for TcR cross-reactivity between epitopes derived from the human genome, the human 
microbiome, and human pathogens, we developed a new immunoinformatics tool, JanusMatrix, that represents an 
extension of the validated T cell epitope mapping tool, epiMatrix. initial explorations, summarized in this synopsis, have 
uncovered what appear to be important differences in the TcR cross-reactivity of selected regulatory and effector T cell 
epitopes with other epitopes in the human genome, human microbiome, and selected human pathogens. in addition to 
exploring the T cell epitope relationships between human self, commensal and pathogen, JanusMatrix may also be useful 
to explore some aspects of heterologous immunity and to examine T cell epitope relatedness between pathogens to 
which humans are exposed (Dengue serotypes, or hcV and influenza, for example). in hand-Foot-Mouth disease (hFMD) 
for example, extensive enterovirus and human microbiome cross-reactivity (and limited cross-reactivity with the human 
genome) seemingly predicts immunodominance. in contrast, more extensive cross-reactivity with proteins contained 
in the human genome as compared to the human microbiome was observed for selected Treg epitopes. While it may 
be impossible to predict all immune response influences, the availability of sequence data from the human genome, 
the human microbiome, and an array of human pathogens and vaccines has made computationally–driven exploration 
of the effects of T cell epitope cross-reactivity now possible. This is the first description of JanusMatrix, an algorithm 
that assesses TcR cross-reactivity that may contribute to a means of predicting the phenotype of T cells responding to 
selected T cell epitopes. Whether used for explorations of T cell phenotype or for evaluating cross-conservation between 
related viral strains at the TcR face of viral epitopes, further JanusMatrix studies may contribute to developing safer, more 
effective vaccines.
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cross-conserved epitopes might be important to remove from vac-
cines, because of the potential for cross-reactive T cells to the vac-
cine epitopes to suppress, or alter, the desired immune response. 
The tool may also be used to uncover pathogen epitopes that 
are associated with autoimmune responses, and epitopes that are 
conserved between two similar pathogens (Dengue serotypes) or 
slightly dissimilar pathogens (West Nile Virus and Yellow Fever 
Virus, for example). The purpose of this review is to describe 
the use of this tool, as it is currently being implemented in our 
research programs, and to illustrate several potential applications 
of JanusMatrix to vaccine research and development.
The mechanics of T cell receptor cross-reactivity. T cells rec-
ognize linear peptides or “T cell epitopes” that form a complex 
with human (HLA) or other species’ MHC molecules. The T cell 
bears a surface receptor (T cell receptor, or TCR) that binds to 
the T cell epitope’s amino acid side chains facing upwards, out of 
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that altering MHC binding residues can modify the affinity of 
the peptide and change the shape of the TCR face, the TCR has 
been shown to adapt to minor changes, enabling a single TCR to 
bind to more than one epitope containing the same TCR-facing 
but different MHC-binding-facing residues.2,3
Rules of contact enable the generation of TCR cross-
reactivity predictions. Based on crystal structures of ternary 
MHC:peptide:TCR structures, general patterns of contact have 
been observed, with some peptide residues frequently in contact 
with the MHC and others frequently in contact with the TCR.4 
These TCR-facing and MHC-facing amino acid residue rules 
can be adapted for use with T cell epitope prediction tools such 
as EpiMatrix5 to define cross-conserved TCR-facing residues 
across large sequence databases (see JanusMatrix algorithm, 
below). Once a single T cell epitope is defined, by holding its 
TCR-facing residues constant and allowing its MHC-binding 
residues to vary, it becomes possible to search protein sequence 
databases for epitopes that appear “homologous” to a given 
TCR, despite minor variations in MHC binding residues, that 
will still be predicted to bind to the same MHC. As a first 
approximation, this approach reduces the number of poten-
tial cross-reactive sequences identified and makes experimental 
validation feasible. In reality, however, TCRs are not required 
to recognize HLA-bound peptides by sequence similarity but 
rather by peptide side chain accessibility.6,7 Consequently, the 
set of potential cross-reactive sequences is very likely dramati-
cally greater and would be unwieldy in initial validation experi-
ments. We believe experimental confirmation in the simplest 
case (identical TCR-facing residues) is a reasonable first step 
to be followed by computational screening of an expanded 
sequence/structure space to capture additional cross-reactive 
epitopes.
TCR cross-reactivity between self and non-self. Cross-
reactivity is an intrinsic characteristic of the TCR, i.e., each sin-
gle TCR can potentially interact with different peptide-MHC 
complexes. In fact, T cell epitope cross-reactivity is critical to 
many aspects of T cell biology, including positive and negative 
selection. Cross-reactive immunity can have either advantageous 
or negative (e.g., leading to pathology) consequences. Deleterious 
autoimmune cross-reactivity can occur following infection, a 
response that has previously been described as molecular mim-
icry. For example, T cell epitope cross-reactive immune responses 
may contribute to the pathogenesis of systemic lupus erythema-
tosus,8 tropical spastic paraparesis,9 and diabetes,10 among other 
conditions. While we have not yet used JanusMatrix to define 
cross-reactivity between human pathogens and T cell epitopes 
associated with auto-immune disease, this is an area of great 
interest that we are likely to pursue in the future.
Heterologous immunity: TCR cross-reactivity between 
pathogens. Heterologous immunity is a term coined by Welsh 
and Selin to describe the partial immunity (or altered immuno-
pathology) that occurs in response to a pathogen if the host has 
been previously infected or immunized with a particular unre-
lated pathogen. Both human and murine immune responses to 
antigens can be modified as a consequence of T cell cross-reac-
tivity.11-13 In some cases, heterologous immunity is attributed to 
the MHC binding cleft, while the MHC binds to the T cell epit-
ope’s amino acid side chains facing into “pockets” located on the 
sides and bottom of the binding cleft. The T cell epitope face that 
binds into the MHC-binding cleft is known as the “agretope”, 
while “epitope” refers to either the whole linear peptide or to the 
TCR face of the peptide (Fig. 1).
Effective T cell immunity requires that the host be able to 
generate a specific response to antigenic epitopes without any 
prior knowledge of their composition. In this regard, the immune 
system faces a fundamental dilemma: how to cover the vastly 
higher number of potential epitopes (estimated at > 1012) with 
available TCRs (estimated maximum of < 108 in humans). One 
hypothesis for resolving this dilemma is that TCRs may recog-
nize more than one peptide epitope. This theory has since been 
validated: indeed, each TCR has the potential to recognize as 
many as one million peptides. The possibility for cross-reactivity 
may seem high and even potentially dangerous, but given the 
number of potential T cell epitopes represented by modifying 
the 20 amino acids at each of the TCR-facing positions, it turns 
out that this reflects a minimum cross-specificity of 1:100,000 
peptides.1 Thus, there is a relatively limited probability of cross-
reactivity with self as well as foreign antigens. While it is true 
Figure 1. JanusMatrix separates the amino acid sequence of T cell epi-
topes into TcR-facing residues and hla binding cleft-facing residues, 
and then compares the TcR face to other putative T cell epitopes. 
JanusMatrix defines cross-reactive T cell epitopes as those that have the 
same Mhc allele restriction, the same or similar T cell-facing residues 
(epitope), and conserved binding of Mhc-facing residues (agretope). 
The hla-facing residues of the comparators are allowed to vary, as long 
as they still bind to the original hla allele. epitopes that are identical 
in terms of their TcR face and are equally able to bind to the identical 
hla, but differ in sequence, are rapidly identified from a given database 
of genomic sequences. This enables large-scale comparisons between 
TcR-homologous T cell epitopes from the hG, the hM, and the hp.
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T cell epitopes for cross-reactivity between the HG and HM; (2) 
understanding the pathogenesis of hepatitis C virus (HCV); and 
(3) the discovery of T effector epitopes in EV71, the etiologic 
agent of Hand-Foot-Mouth disease (HFMD). For these initial 
studies, we applied JanusMatrix retrospectively to explore cross-
reactive patterns of previously studied epitopes that induced 
various T cell responses, as well as prospectively to identify and 
experimentally evaluate new cross-reactive epitopes predicted to 
induce various responses.
Results
Developing epitope “silos”. Using EpiMatrix and JanusMatrix, 
we mapped groups of peptides that were experimentally shown to 
induce a defined T cell response (Teff, Treg, or no response) and 
searched for trends in the number of cross-reactive TCR-facing 
epitopes across the HG, HM, and HP databases supported by 
JanusMatrix. A set of 10,000 random nine-mers was also evalu-
ated for comparison.
Based on cross-reactivity patterns, T cell epitopes examined 
thus far appear to fall into one of three categories, or “silos”: (1) 
patterns that are characteristic of Treg epitopes; (2) patterns that 
are characteristic of Teff epitopes; and (3) patterns associated 
with epitopes that are “null” (neither effector nor regulatory but 
are predicted to bind to HLA). We find these distinctive cross-
reactivity patterns are generally correlated with the types of T 
cell epitopes defined in the literature. Specifically, T cell epitopes 
that appeared to be immunodominant were associated with Treg 
responses, as defined by upregulation of FoxP3 or expansion of 
CD4+CD25hi Treg, and had higher levels of cross-reactivity with 
the HG.
Table 1 describes the emerging JanusMatrix patterns associ-
ated with T cell epitope categories (Treg, Teff) and provides an 
example for each category (a defined Treg epitope for HCV35-37 
and a defined Teff epitope in influenza38) in terms of their TCR 
cross-reactivity with the HG, HM, and selected human viral 
and bacterial pathogens (HP). “CEFT” epitopes that are com-
monly used as positive controls in human T cell assays to elicit 
a measurable antigen-specific memory response (see list of these 
epitopes in ref. 39) and Tregitopes (see ref. 40) were tested as 
representative sets of T effector and T regulatory epitopes respec-
tively. Medians and ratios of cross-reactive hits are shown. We 
also describe cross-reactivity that could be expected in a ran-
dom protein: 10,000 random nine-mers predicted to be HLA 
ligands show the lowest median of cross-reactive hits for each 
database analyzed. Number of genomes, proteins, and amino 
acids per database is also shown. Results of the statistical analysis 
(P-values) of the comparison between the distributions of ratios 
of cross-reactive hits between databases and types of epitopes are 
also shown in sub-tables. Comparisons between type of epitopes 
by database (e.g. CEFT vs. Treg for HG; see sub-table A) show 
that (1) Treg and CEFT are only different for HG; and (2) for 
the three databases, CEFT and Tregs are different from random; 
the only exception is the comparison of HP CEFT vs. Random. 
Comparisons between databases by type of epitope (e.g. HG vs. 
HM for CEFT; see sub-table B) we observe that (1) for CEFT, 
T cells that cross-react with both pathogens. CD8+ T cell cross-
reactivity has been documented between two epitopes on the 
same viral protein, between epitopes of different proteins from 
the same virus and, more importantly, between epitopes of pro-
teins from different viruses.14
Heterologous immunity research focused initially on specific 
viral infections (e.g., vaccinia, EBV, influenza).15,16 It is now clear 
that T cells stimulated by epitopes from a given pathogen may 
subsequently respond differently to cross-reactive similar epit-
opes with later infection by a different virus.17 T cells that have 
been previously activated due to a cross-reactive infection are 
capable of restricting pathogen growth and reducing the severity 
of the second infection, which can be viewed as a positive effect. 
In the context of some infections caused by different viruses, 
heterologous immunity may contribute to the immunodomi-
nance of low-avidity memory responses over higher-avidity naïve 
responses. However, in other circumstances, the result of cross-
reactive immunity is enhanced pathogen growth and/or immu-
nopathology.18 Proposed mechanisms underlying these negative 
effects may include induction of Treg or, in contrast, increased 
production of inflammatory cytokines.11,19-21 JanusMatrix is cur-
rently being used to search for epitopes that may contribute to 
heterologous immunity.
The relevance of the HM to adaptive T cell responses. 
Evidence linking gut microbes, adaptive immunity, metabolic 
syndrome, allergy, and autoimmune disorders has emerged.22,23 
For example, linkages between immune responses to the HM 
and multiple sclerosis have been defined,23 as have links between 
microbiota and autoimmune diseases of the gut.24,25 Exposure 
to a diverse array of gut microbes may reduce susceptibility to 
autoimmune diseases and allergy (the so-called “hygiene hypoth-
esis”).22,23,26 This may be attributable to direct interactions 
between the microbes and the human immune system (due to 
not-yet-defined factors) or to modulation of immune responses 
to self and other potential pathogens.24,27-29
In addition, there is a growing body of evidence that the gut 
microbiome shapes adaptive immune responses.27,30,31 Notably, 
post-thymic educated gut CD4+ T cells differentiate to become 
inducible Treg by training on commensal antigens.32 This finding 
is significant because it establishes the existence of T cells with 
specificities for commensals, which may cross-react with patho-
gen- or vaccine-derived sequences. Since the gut microbiome is 
both vast and highly variable, it is likely that commensal-shaped 
immune responses are highly diverse and vary from person to 
person due to individual variations in the microbiome (related 
to diet or geography) and to genetic differences in HLA. In pub-
lished33 and yet-to-be-published34 work, Sztein and VerBerkmoes 
have established the uniqueness and commonalities between 
individual microbial and human proteomes.
The availability of fast and accurate tools to analyze a large 
number of sequences for common TCR-facing residues now 
makes it both feasible and exciting to examine the role that cross-
reactive T cell epitopes play in the generation of autoimmune and 
the modulation of adaptive immune responses. In the next sec-
tion, we provide a brief description of the JanusMatrix tool and 
its application to: (1) evaluations of common “positive control” 
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are compared (p = 0.1; Table 1). However, the HLA allele for 
which the predicted nine-mer ligand with the highest number 
of cross-reactive hits with HG, HM, and HP is not the same 
allele for which immunogenic response to CEFT 09 is reported. 
This may suggest that the peptide contained within the larger 
epitope induces a null (tolerant) or Treg response for individuals 
possessing the predicted cross-reactive HLA.
Example 2. Viral HP. We recently mapped T cell epitopes for 
EV71, the enterovirus that has been responsible for several out-
breaks of HFMD in Asia.41 We found that extensive cross-reac-
tivity with HM seemed to be associated with immunodominance 
(Fig. 3). Shown in the figure are the T cell epitopes that were 
tested in HFMD patients. One of the two immunodominant 
epitopes (NTAYIIALAAAQKNFTMKL) was highly cross-
conserved with enteroviruses such as polio virus (not shown) 
and with the human microbiome and pathogen sequences 
(Fig. 3). As is described in greater detail in the original paper, 
cross-reactivity between EV71 and poliovirus, appeared to be 
linked to protection from severe HFMD and thus may be an 
example of beneficial cross-reactive T cell responses.
Example 3. Human Treg epitopes from Hepatitis C. For a set of 
Treg epitopes that were previously defined in HCV disease, HG 
cross-reactivity appears to be much more extensive than HM. 
Overall, greater cross-reactivity with HG seems to distinguish 
published Treg and Teff epitopes from the same viral pathogen 
(Fig. 4).
the distributions of the ratios of cross-reactive hits of the three 
databases are not different; (2) for Tregs, HG is different from 
both HM and HP and HM is not different from HP; and (3) for 
random peptides, HG, HM, and HP are all different.
In summary, these results indicate that validated Treg epi-
topes have statistically greater TCR cross-reactivity with the 
human genome, based on JanusMatrix. Teff and Treg cross-
reactivities with HG, HM, and HP are different from random 
nine-mers (Teff vs. Random for HP is the exception). Teff dis-
tributions of the ratios of cross-reactive hits are not different 
between databases. Some of the overlap between HP and HM 
and HG might be due to co-opting of HG cross-reactivity by 
human pathogens to escape immune response. Cytoscape-based 
TCR-epitope network patterns for the HCV Treg epitope and 
influenza Teff epitope are shown in Figure 2.
Illustration of JanusMatrix patterns. Example 1. “Positive 
control” T cell epitopes (Table 2). We had previously evalu-
ated these 15 CEFT epitopes for MHC binding affinity, using 
EpiMatrix and found that their reported MHC restriction was 
highly correlated with EpiMatrix predictions, and that most 
epitopes were also predicted to bind to a number of additional 
MHC class II alleles with high affinity.39 Although the median 
number of cross-reactive hits between these T cell epitopes and 
the HM (Median = 29, SD = 68.03) is different from the median 
number of hits with the HG (Median = 2, SD = 5.96), no sig-
nificant difference is found when the ratios of cross-reactive hits 
Table 1. JanusMatrix TcR-cross reactivity frequencies for three types of epitopes
Database
Median cross-reactive hits (Ratio, 1 x 106)a
T eff epitopes Treg epitopes Random Per database, number of
CEFT Influenza A Tregs HCV Genomes Proteins Amino acids
Self  
(hG)
2 (0.18) 0 (0.00) 8.5 (0.75) 23.5 (2.08) 1 (0.09) 1 20,248 11,301,336
Microbiome 
(hM)
29 (0.13) 38 (0.17) 31 (0.14) 103 (0.47) 14 (0.06) 204 705,684 218,452,796
pathogens 
(hp)
17 (0.12) 11 (0.08) 19 (0.13) 107.5 (0.73) 10 (0.07) 221 455,237 146,398,849
A
Epitope type HG HM HP
Treg vs. ceFT <0.05 0.63 0.62
ceFT vs. Random <0.05 0.05 0.11
Treg vs. Random <0.05 <0.05 <0.05
B
Database CEFT Treg Random
hG vs. hM 0.10 <0.05 <0.05
hG vs. hp 0.24 <0.05 <0.05
hM vs. hp 0.50 0.15 <0.05
aRatio of cross-reactive hits per number of amino acids in the comparison database. bNine-mer predicted to be an epitope. (A) p-values of comparisons 
between ratios across three types of epitopes by database. (B) p-value of comparisons between ratios across databases by type of epitope. Median of 
cross-reactive hits for T effector epitopes, T regulatory epitopes, and Random 9-mers are shown. ceFT and Tregs are tested as representative sets of T 
effector and T regulatory epitopes. examples for both categories are also included; a defined Teff epitope in influenza a and a Treg epitope for hcV. TcR 
cross-reactivity with hG, hM, and selected human viral and bacterial pathogens (hp) was evaluated. Ratios of cross-reactive hits by number of amino 
acids in the comparison database are shown in parenthesis. Number of genomes, proteins, and amino acids per database is also shown. analyses were 
preformed with a 95% confidence level. 
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exposure to a new pathogen or to a vaccine containing the 
conserved T cell epitope. In contrast, cross-reactivity between 
pathogens (or commensals) might redirect the immune response 
towards suboptimal epitopes or enhance cytokine responses to 
vaccine antigens, contributing to vaccine-related adverse events. 
T cells activated by vaccination can also have cross-reactivity 
with self-antigens.45,46 This can lead to the breakdown of tol-
erance mechanisms and subsequent autoimmune reactions. 
Autoimmune reactions such as myocarditis, Guillain-Barré 
syndrome, and vasculitis have been described after administra-
tion of several vaccines,47-52 but their cause is not fully under-
stood. The JanusMatrix tool may be particularly valuable for 
future explorations of immune-mediated adverse responses to 
vaccination.
JanusMatrix may also be useful for defining homologous T cell 
epitopes among variant strains or serotypes of the same pathogen. 
For example, use of these defined rules to search for conserved 
TCR-facing residues in large Dengue sequence databases may 
contribute to understanding the immunopathogenesis of Dengue 
Hemmorhagic Fever, a severe manifestation of Dengue infection. 
In addition, the use of the tool may uncover important similari-
ties between HIV and the human genome, that have long been 
surmised but not yet validated.
Aspects of JanusMatrix analysis that may lead to inaccu-
rate predictions. The current analysis relies on the accuracy 
of the EpiMatrix epitope prediction tool, as well as the care-
ful curation of protein sequences in each of the analyzed data-
bases. While each of these sources is most certainly subject to 
some error, the large deviations in the frequencies (see Table 1) 
that we are observing seem to suggest that cross-reactivity at the 
Discussion
The future: two-faced epitopes. Using the newly developed 
algorithm JanusMatrix, we have begun to expand the informa-
tion available on the role of T cell epitopes conserved between 
the HM, HG, and HP, and to understand how these epitopes 
may influence the immune response. We are applying the tool 
to examine whether exposure to human commensals alters 
subsequent T cell responses to common human pathogens and 
to re-examine prevailing paradigms related to autoreactive T 
cells. This approach, in which we define a T cell epitope based 
on a well-established T cell epitope-mapping algorithm,42,43 is 
significantly different from previous analyses.44 JanusMatrix 
compares putative T cell epitopes and their TCR-facing resi-
dues across genome sequences rather than linear peptide 
fragments.
JanusMatrix may enable the definition of microbial T cell epit-
opes that contribute to host-microbial homeostasis. As disruption 
of microbial homeostasis may contribute to autoimmunity, and 
other pathological processes, the availability of the JanusMatrix 
tool could significantly advance the understanding of and treat-
ment for autoimmune and other disorders. The extensive cross-
reactivity of TCR-facing residues across genomic sequences and 
the distinct patterns of cross-reactivity associated with T cell phe-
notype may have important implications for the development of 
vaccines and for vaccine safety and efficacy, as T cells activated 
by cross-reactive HM epitopes can exhibit differential ability(ies) 
to respond to vaccine antigens.
Cross-reactive T cells such as those described for HFMD and 
other enteroviruses may enhance immune responses following 
Figure 2. TcR-epitope Networks (developed using cytoscape) for regulatory T cell epitopes (A) and effector T cell epitopes (B). epitopes with TcR-
facing residues similar to each of the test epitopes were identified in protein sequences from the human genome (hG; left), human microbiome (hM; 
center), and human viral and bacterial genomes (hp; right) databases. Green diamonds represent source peptides; gray squares are predicted nine-
mer epitopes derived from the source peptide (predicted using epiMatrix); blue triangles are nine-mers that are 100% identical to the TcR face of the 
source epitope and that are predicted to bind to the identical hla; and light purple circles are proteins containing the cross-reactive epitope.
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median number of cross-reactive hits for 1 million random nine-
mer sequences. This would create a norm and standard devia-
tions against which all other epitopes could be compared, and 
also make it possible to report deviations from the norm for each 
genome as a Z-score.
Population vs. individual specificity. We also note that the 
JanusMatrix predictions are performed at the population-wide 
level and are not based on any individual HLA type. Even if 
TCR level may indeed influence T cell phenotype. We also note 
that the sheer volume of genomic data that is available in the HP 
and HM databases, compared to that of the HG may obscure 
important pattern differences, and that redundancies in epit-
opes between pathogens may further obscure differences; future 
iterations of this tool will allow a slight discount or ‘weight-
ing’ of redundant epitopes. We also plan to normalize the com-
parisons of cross-reactive hits for each genome by defining the 
Table 2. JanusMatrix analysis of the ceFT peptide pool
Number of cross-reactive hits
Source Reported allele Peptide sequence Nine-mer Alleles HG HM HP
ceFT 01 DR4 FVFTlTVpSeR FVFTlTVpS 6 4 29 54
VFTlTVpSe 1 0 8 6
FTlTVpSeR 4 6 31 40
ceFT 02 DR1 SGplKaeiaQRleDV lKaeiaQRl 4 5 65 43
ceFT 03 DR1 YDVpDYaSlRSlVaSS YaSlRSlVa 7 7 49 68
ceFT 04 DR1 pYYTGehaKaiGN YTGehaKai 3 0 5 6
ceFT 05 DR3 GQiGNDpNRDil iGNDpNRDi 1 0 1 0
ceFT 06/07 DR1, DR4 pKYVKQNTlKlaT YVKQNTlKl 8 5 180 96
VKQNTlKla 2 2 23 18
ceFT 09 DR15 aGlTlSllVicSYlFiSRG aGlTlSllV 1* 33 336 364
TlSllVicS 1 2 18 11
llVicSYlF 5 0 14 7
VicSYlFiS 1 1 3 2
icSYlFiSR 1 2 17 2
ceFT 10/11 DR8, DR11, DR13, DR15 QYiKaNSKFiGiTel YiKaNSKFi 8 2 104 76
iKaNSKFiG 5 4 102 64
ceFT 12 DR7, DR11 FNNFTVSFWlRVpKVSaShle FNNFTVSFW 1 0 2 2
FTVSFWlRV 2 2 8 14
FWlRVpKVS 4 0 5 3
WlRVpKVSa 4 5 64 44
lRVpKVSaS 2 2 30 12
ceFT 13 DR1 TSlYNlRRGTala lYNlRRGTa 4 0 39 9
YNlRRGTal 5 4 31 34
ceFT 15 DR11 VSiDKFRiFcKalNpK VSiDKFRiF 1 0 12 9
FRiFcKalN 4 6 25 23
ceFT 17 DR8 DKReMWMaciKelh MWMaciKel 1 0 0 1
WMaciKelh 1 1 47 17
ceFT 19 DR3 KelKRQYeKKlRQ lKRQYeKKl 5 3 67 17
KRQYeKKlR 2 5 71 33
ceFT 22 DR4 aeGlRallaRShVeR lRallaRSh 5 12 167 220
llaRShVeR 2 3 41 43
ceFT 23 DR7 pGplReSiVcYFMVFlQThi lReSiVcYF 1 0 6 2
YFMVFlQTh 1 0 4 1
*immunogenicity for this peptide is not reported for the predicted allele (DR7), suggesting that the nine-mer peptide contained within the larger 
epitope may induce a null (tolerant) or Treg response for individuals possessing this hla.
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Methods
JanusMatrix tool development. As implied by its name,a 
JanusMatrix examines predicted T cell epitopes from both the 
HLA-binding and TCR-facing perspectives, identifying as 
potentially cross-reactive those that are predicted to bind the same 
HLA (though perhaps with different amino acid composition on 
the HLA-facing side) while presenting the same amino acids to 
the TCR (Fig. 1). Given a starting protein sequence, putative T 
cell epitopes are first identified using the EpiMatrix epitope-pre-
diction tool. The JanusMatrix tool parses the epitopes into nine-
mer frames and divides each nine-mer into T cell receptor-facing 
residues and MHC-binding residues, based on defined rules from 
the literature.54 Specifically, for Class I: TCR facing residues are 
considered to be residues 4, 5, 6, 7, 8, and for Class II: 2, 3, 
5, 7, 8. JanusMatrix then searches for potentially cross-reactive 
TCR-facing epitopes across any number of large sequence data-
bases that have been pre-loaded into the tool, including the HM, 
the HG, and HP. JanusMatrix focuses in 9-mer searches because 
although peptides of different lengths interact with the MHC, 
most T cell epitopes can be mapped to a minimum of nine or 10 
amino acids in any given peptide, even if the peptide is longer.55,56 
Future versions of the algorithm will include 10-mer as well as 
9-mer searches.
Sequence databases. We have integrated available sequence 
datasets into our JanusMatrix toolkit so as to uncover potentially 
cross-reactive epitopes between self and microbes, including 
the HG,57 HM,58 and bacterial59 and viral 60 proteomes that we 
have compiled into one HP database.The number of genomes, 
proteins, and amino acids per database was determined. In 
addition, we have access to unpublished databases comprising 
“frequently expressed proteins” of the HM, courtesy of Sztein 
the general observation of the relationship between cross-reac-
tivity and T cell phenotype holds true, these findings may vary 
from individual to individual based on their HLA, their history 
of exposures to vaccines and human pathogens, and their gut 
microbiome.
Furthermore, it is likely that cross-reactive immune responses 
are due to a diverse set of TCR-peptide-MHC interactions. 
Rather than being defined by a single cross-reactive T cell 
clone, it is likely that many different T cells, each with a unique 
TCR, respond to cross-reactive epitopes. Each clonal TCR that 
interacts with a set of peptide-MHC complexes (pMHC) may 
respond with a different set of effector functions. Consequently, 
specific patterns of cross-reactive immunity may occur only in 
certain people due to individual variation in the pMHC-specific 
T cell repertoire (“private specificity”).53 Nonetheless, detailed 
understanding of these cross-reactive immune responses to prior 
exposures, and the relatedness of these responses to HLA, may 
lead to better vaccine designs and significant improvements in 
vaccine efficacy.
The future. Due to advances in computational power, the 
availability of vast genome sequences from commensals and 
pathogens to which humans are exposed, and the development 
of algorithms such as JanusMatrix, it is now possible to begin 
exploring the HM-HG and HP-HG intersections at the level of 
the T cell epitope. No comprehensive effort to uncover the con-
servation of HM epitopes across different pathogens and self pro-
teins has been published to date, nor has the available literature 
defined a set of generalizable principles underlying T cell cross-
reactivity that would permit predictions to be experimentally 
tested in a prospective manner. We expect that the exploration of 
the two-faced T cell epitope using JanusMatrix will significantly 
advance human immunology in this respect.
Figure 3. hand-Foot-Mouth Disease (hFMD) epitope conservation in human microbiome/human pathogen genome sequence and immunodomi-
nance. The figure shows the potential importance of cross-reactivity between microbial genomes to the immunodominance of a particular epitope. 
in hFMD, extensive cross-reactivity with the hM seems to predict immunodominance. Y axis: number of cross-reactive hits in the database; x axis, 
individual epitopes (and nine-mers within those epitopes).
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contain them, with edges between cross-reactive pairs of epitopes 
and between the proteins and their constituent epitopes. We have 
incorporated Cytoscape61 into the JanusMatrix toolkit so as to 
interactively visualize relatedness between selected T cell epitopes 
and target genomes (HG, HM, HP) and to describe the result-
ing epitope networks. In the examples provided in Results, we 
used JanusMatrix, EpiMatrix v1.2,62 and the genome databases 
described above. Ratios of the cross-reactive hits per amino acids 
in the comparison database (HG, HM, or HP) were calculated 
for comparison purposes. Since the distributions of the ratios of 
cross-reactive hits were not normally distributed, non-parametric 
tests (Wilcoxon-Mann-Whitney test and Wilcoxon rank sum 
test) were used to evaluate differences in the distributions of ratios 
of cross-reactive hits between databases. Two type of comparisons 
were performed: (1) Comparisons between ratios across types of 
epitopes (Teff vs. Treg, Teff vs. Random, and Treg vs. Random) 
by database, and (2) comparisons between ratios across databases 
(HG vs. HM, HG vs. HP, and HM vs. HP) by type of epitope. 
All the analyses were performed with a 95% confidence level.
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These authors acknowledge that there is a potential conflict of 
interest related to their relationship with EpiVax and attest that 
and VerBerkmoes (method described in ref. 24). The HM data-
base of expressed peptide sequences was created from the most 
extensive healthy human-microbial distal gut metaproteome 
available to date.33 In order to obtain the metaproteome, cells 
are enriched from fecal samples via differential centrifugation. 
The samples are then enriched in microbial cells and thus had 
a higher abundance of microbial proteins while still contain-
ing large amounts of interacting human proteins. The mixed 
human-microbial proteome was lysed, denatured, and reduced 
with 6 M Guanidine/10 mM DTT, and subsequently digested 
into peptides with sequencing grade trypsin (Sigma). The com-
plex peptide mixture was analyzed via shotgun proteomics on 
a 2d-LC-MS/MS system (Linear Ion trap Orbitrap). The resul-
tant MS/MS spectra were searched against a combined human 
(human ref seq) and microbial isolates database (JGI-IMG HM 
database). Proteins were computationally assembled from iden-
tified peptides (strictly filtered at ~1% false positive rate). The 
entire dataset from both subjects was extracted for all identified 
peptides and proteins and was provided as an annotated database 
for upload into Janus Matrix.
Computational methods. JanusMatrix builds upon the 
EpiMatrix epitope predictor, processing each genome to iden-
tify TCR-facing cross-conserved HLA-binding nine-mers.37,41,43 
In addition to identifying cross-reactive epitopes and describing 
these in tabular format, we have found it useful to visualize the 
patterns with “epitope networks” using Cytoscape. An epitope 
network has nodes for the epitopes and for the proteins that 
Figure 4. hepatitis c virus (hcV) epitope conservation in human microbiome/human pathogen genome sequence and immunodominance. For 
regulatory T cell epitopes defined in hcV disease, hG cross-reactivity is more extensive. overall, greater cross-reactivity with hG, hM, and hp seems 
to distinguish published Treg and T effector epitopes. The exact parameters defining “greater” and “lesser” cross reactivity remain to be defined fol-
lowing the evaluation of a number of well-defined Treg and T effector epitope examples. Y axis: number of cross-reactive hits in the database; x axis, 
individual epitopes (and nine-mers within those epitopes).
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Endnote
aIn Roman mythology, Janus is “god of beginnings and transi-
tions”, of gates, doors, doorways, endings and time. He is usually 
portrayed as a two-faced god since he looks to the future and the 
past.
the work contained in this research report is free of any bias that 
might be associated with the commercial goals of the company.
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